Volumetric Growth Rate of Stage I Lung Cancer prior to Treatment: Serial CT Scanning
Abstract
PURPOSE: To determine the range of growth rates of stage I lung cancers prior to treatment by using volumetric measurement at serial chest computed tomographic (CT) examinations.
MATERIALS AND METHODS: The study population comprised 50 patients who underwent two CT examinations at 25-day or greater intervals. Tumor craniocaudal length and cross-sectional diameters and perimeters were used to volumetrically model each tumor in three ways (spherical, elliptical, perimeter). Volumes were compared by determining Pearson correlation coefficients. By using these volumes, tumor doubling time was determined for each patient.
RESULTS: Volumes measured with all three methods were highly correlated. With the perimeter method, median doubling time was 181 days, with a very wide range. Eleven (22%) of 50 tumors had doubling times of 465 days or more. There was considerable overlap in doubling time between histologic subtypes. Assuming constant growth, only three (6%) of the 50 tumors would have been the size of a stage IA tumor for less than 1 year.
CONCLUSION: Comparison of tumor volumes at serial CT examinations reveals a very wide range of growth rates. Some tumors grow so slowly that biopsy is required to prove they are malignant.
© RSNA, 2002
References
- 1 Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717.
- 2 Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96:440-447.
- 3 Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70:1102-1110.
- 4 Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99-105.
- 5 Swenson SJ. Lung cancer screening: low-dose CT. Presented at the 18th Annual Meeting of the Society of Thoracic Radiology, San Diego, Calif, March 12–16 2000.
- 6 Sone S, Takashime S, Li P, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351:1242-1245.
- 7 Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201:798-802.
- 8 Steele JD, Buell P. Asymptomatic solitary pulmonary nodules: host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg 1973; 65:140-151.
- 9 Weiss W, Boucot KR, Cooper DA. Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA 1966; 198:1246-1252.
- 10 Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 1974; 65:3-8.
- 11 Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer 1963; 16:694-707.
- 12 Garland LH. The rate of growth and natural duration of primary bronchial cancer. Am J Roentgenol Radium Ther Nucl Med 1966; 96:604-611.
- 13 Hasagawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 2000; 73:1252-1259.
- 14 Yankelevitz DF, Reeves AP, Kostis WJ, Zhao B, Henschke CL. Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation. Radiology 2000; 217:251-256.
- 15 Yankelevitz DF, Gupta R, Zhao B, Henschke CI. Small pulmonary nodules: evaluation with repeat CT—preliminary experience. Radiology 1999; 212:561-566.
- 16 Geddes DM. The natural history of lung cancer: a review based on rates of tumor growth. Br J Dis Chest 1979; 73:1-17.
- 17 Nathan MH, Collins VP, Adams RA. Differentiation of benign and malignant pulmonary nodules by growth rate. Radiology 1962; 79:221-231.
- 18 Weiss W. Peripheral measurable bronchogenic carcinoma: growth rate and period of risk after therapy. Am Rev Resp Dis 1971; 103:198-208.
- 19 Usuda K, Saito Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994; 74:2239-2244.
- 20 Aoki T, Nakata H, Watanabe H, et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 2000; 174:763-768.
- 21 Staron RB, Ford E. Computed tomographic volumetric calculation reproducibility. Invest Radiol 1986; 21:272-274.
- 22 Spratt JA, von Fournier D, Spratt JS, Weber EE. Decelerating growth and human breast cancer. Cancer 1993; 15:2013-2019.
- 23 Xu XL. The biological foundation of the Gompertz model. Int J Biomed Comput 1987; 20:35-39.
- 24 Blomqvist C, Wiklund T, Tarkkanen M, Elomaa I, Virolainen M. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Br J Cancer 1993; 68:414-417.
- 25 Miller CW. Growth characteristics of pulmonary metastases from osteosarcoma. Clin Orthop 1976; 116:70-75.
- 26 Trott KR, Heinze HG, Kiesel B, Kollmann G, Kummermehr J. Growth rate of pulmonary metastases. Strahlentherapie 1979; 155:748-753. [German].
- 27 Martini N, Bains NS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120-129.
- 28 Patz EF, Rossi S, Harpole DH, Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000; 117:1568-1571.
